Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petr Pavlicek

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
BMC Cancer|April 9, 2025
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma GroupJiri Minarik, Ludek Pour, Vojtech Latal, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
International Journal of Laboratory Hematology|January 16, 2021
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmationJakub Radocha, Tomas Jelinek, Ludek Pour, et al.
Leukemia Research|July 13, 2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma GroupJiri Minarik, Viera Sandecka, Vladimir Maisnar, et al.
Leukemia|July 11, 2021
Limited efficacy of daratumumab in multiple myeloma with extramedullary diseaseTomas Jelinek, Tereza Sevcikova, David Zihala, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
Blood Cancer Journal|September 26, 2023
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal GammopathiesViera Sandecka, Tereza Popkova, Martin Stork, et al.
BMC Cancer|January 16, 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceJiri Minarik, Tomas Pika, Jakub Radocha, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
BMC Cancer|April 9, 2025
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma GroupJiri Minarik, Ludek Pour, Vojtech Latal, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
International Journal of Laboratory Hematology|January 16, 2021
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmationJakub Radocha, Tomas Jelinek, Ludek Pour, et al.
Leukemia Research|July 13, 2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma GroupJiri Minarik, Viera Sandecka, Vladimir Maisnar, et al.
Leukemia|July 11, 2021
Limited efficacy of daratumumab in multiple myeloma with extramedullary diseaseTomas Jelinek, Tereza Sevcikova, David Zihala, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
Blood Cancer Journal|September 26, 2023
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal GammopathiesViera Sandecka, Tereza Popkova, Martin Stork, et al.
BMC Cancer|January 16, 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceJiri Minarik, Tomas Pika, Jakub Radocha, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.
Pageof 2